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A short-term in vitro test for tumour sensitivity to
adriamycin based on flow cytometric DNA analysis
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The Finsen Institute, and 2The University Institute ofPathological Anatomy, Copenhagen, Denmark.
Summary A new method to test the sensitivity of tumour cells to chemotherapy is presented. Tumour cells
were incubated in vitro on agar, and drug-induced cell cycle perturbation was monitored by flow cytometric
DNA analysis. In the present study the method was applied to monitor the effect of adriamycin on an
adriamycin-sensitive Ehrlich ascites tumour and two adriamycin-resistant tumours. Adriamycin caused a dose-
related accumulation of tumour cells in the G2 + M phase in the sensitive tumour. Drug concentrations 2 100-
fold higher were required to induce similar changes in the resistant tumours. The dose level causing maximum
accumulation in the G2 +M phase is suggested as a parameter for quantifying the sensitivity. The results
indicate that the method can be extended to sensitivity testing of human tumours.
A major problem in cancer chemotherapy is the
wide range of responsiveness even for tumours of
identical histopathological types (Salmon et al.,
1978; Wilson & Neal, 1981). Methods for
individually-guided therapy based on in vitro
sensitivity testing of the tumours would therefore be
of great importance, and the development of a
predictive test for chemosensitivity has a high
priority in cancer research (Hamburger, 1981). A
currently-used test is based on measuring the drug-
induced inhibition of the colony-forming ability of
tumour cells grown in soft agar (Hamburger &
Salmon, 1977). However, the very low colony-
forming efficiency of human malignant tumours
involves the risk of the test not being representative
of the majority of the tumour cells. Furthermore,
observation periods of several weeks are required
before results are obtained.
In recent years, the development of flow
cytometric DNA analysis has made it possible to
obtain rapid information on tumour DNA index,
and on the percentage of cells in the cell cycle
phases (Barlogie et al., 1978; Christensen et al.,
1978). Furthermore, drug-induced perturbations of
the cell cycle distribution of tumours responding to
chemotherapy were demonstrated by flow
cytometric DNA analysis on tumour tissue
obtained by sequential fine-needle aspirations
(Vindelov et al., 1982, 1983). These observations
formed the basis for the development of a new in
vitro method for determination of chemosensitivity.
Tumour cells are incubated in vitro with the agent
F, and the cell cycle perturbations are monitored by
flow cytometric DNA analysis.
In this study the method was tested on three
well-characterized Ehrlich ascites tumours: a wild-
type tumour, sensitive to adriamycin, and two
sublines selected for resistance to adriamycin. The
cell cycle effect of adriamycin is ascribed to a DNA
interaction causing a premitotic block with an
accumulation of cells in the G2 phase (Gohde et al.,
1975; Barlogie et al., 1976). The results showed that
the cell kinetic effect of adriamycin on the three
Ehrlich ascites tumours could be measured by flow
cytometric DNA analysis after short-term in vitro
incubation. Adriamycin caused a dose-related
accumulation of tumour cells in the G2+M phase
in the sensitive tumour. Drug concentration 100-
fold higher were required to induce similar changes
in the resistant tumours.
Materials and methods
Tumours
Three Ehrlich ascites tumours (Dan0, 1971; 1972a;
1972b; Skovsgaard, 1977a; 1977b; 1979) were kindly
supplied by Dr. T. Skovsgaard, Dept. Internal
Medicine, Finsen Institute, Copenhagen. One of the
tumours ("wild-type") was sensitive to adriamycin
(as well as to other anthracyclines) and was
previously found to be hypotetraploid. The other
two tumours were adriamycin-resistant and were
previously characterized as hypotetraploid and
hyperdiploid, respectively. Tumour cells used in the
experiments were harvested 6-8 days after i.p.
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transplantation of 0.2ml undiluted ascitic fluid. The
yield was - 109 cells per mouse. Before use the
cells were washed in PBS (230g for 5 min.).
Incubation procedures
Tumour cells were suspended in Eagle's minimal
essential medium (MEM) containing Earle's salts
supplemented with 20% foetal bovine serum (FBS),
MEM amino acids (50x, 10mll-W medium) and
MEM vitamins (100 x, 10ml 1- 1), L-glutamine
(10mll 1), glucose 10% (5ml-1), gentamycin
(0.002mgml-1), mycostatin (10uml-I ), and
adriamycin (Farmitalia Carlo Erba SpA) in
different concentrations. To 1.Oml of this medium
1.0ml cell suspension was added. Hereby final
concentrations of 10-1 to 10-6mg adriamycin per
ml medium were reached, and a cell concentration
of 106ml-1. Control cell suspensions were prepared
as described, but without the addition of
adriamycin.
The changes in the cell cycle phases of the 3
tumours in vitro were studied by plating tumour
cells from each tumour in 35 mm plastic Petri
dishes. Aliquots of 1.Oml cell suspension (106 cells)
were plated on top of a layer of hardened 0.25%
agar (Difco) containing 26% FBS, 2.5% (by vol)
sheep red blood cells, and mercapto-ethanol
(5 x 10- M) and incubated at 37°C in a humidified
atmosphere of 5% CO2 in 95% air. Cells for flow
cytometric DNA analysis were harvested with a
pipette. After gentle washing of the agar surface
and reharvesting, the dishes appeared cell-free by
microscopic examination. Duplicates of samples
were analysed separately from day 0-18.
The adriamycin incubation was performed with
two different procedures.
1. The one hour incubation procedure Aliquots of
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1.0ml cell suspension (106 cells) were incubated
with 1.0ml medium containing adriamycin in
35mm Petri dishes. The Petri dishes were kept at
37°C in a humidified atmosphere of 5% CO2 in
95% air for 1 h. After the incubation the cells were
washed twice (230g for 5 min.) in PBS and replated
in 1.Oml fresh medium without adriamycin on agar
as described above. The cells for flow cytometric
DNA analysis were harvested as described above
on consecutive days from 0-4.
2. The continuous incubation procedure Aliquots of
1.Orml cell suspension (106 cells) and 1.0ml
adriamycin suspensions were plated on agar at
once, and adriamycin was present throughout the
experiment. In order to avoid light-induced
inactivation of adriamycin, the Petri dishes were
kept in the dark during the incubation. Samples for
flow cytometric DNA analysis were harvested on
days 0, 1/2, 1,2,3, and 4.
Flow cytometric DNA analysis
The flow cytometer used was a FACS III cell
sorter. The tumour cells for flow cytometric DNA
analysis were stored and prepared as described
elsewhere (Vindel0v et al., 1983). The DNA
distribution was analysed with a computer
programme calculating the fractions of cells in the
cell cycle phases (Christensen et al., 1978). In this
study the number of cells analysed for each
histogram was approximately 5x 104. The CV of
the G1 peak was calculated for all histograms and
ranged from 0.02-0.05.
Results
The initial DNA histograms (Day 0) are shown in
Figure 1, and the changes in the cell cycle phases of
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Figure 1 DNA distributions of the 3 Ehrlich ascites tumours used in the experiments, before plating on agar.
The parts of the histograms produced by G1-, S- and G2+M-cells are indicated in a-c. The peak marked D
corresponds to diploid mouse cells.
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the 3 untreated tumours after plating in vitro are
shown in Figure 2. The changes were identical in
the 3 tumours. On day 1 there was an increase in
the fraction of cells in the S phase and a
corresponding decrease in G1 fraction. On days 2-5
the S fraction decreased to - 20%, and the G1
fraction increased to 70%. From day 5, only
minor changes took place. The G2 + M fraction was
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Figure 2 Percentages of cells in the cell cycle phases
as a function of time after plating. (a) the "wild-type"
tumour, (b) the near-tetraploid adriamycin-resistant
tumour, (c) the hyperdiploid adriamycin-resistant
tumour. (G (A), S (0), G2 +M (x).
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unchanged throughout the experiment. The cultures
were confluent 8-12 days after plating.
The effect on the G2+M fraction of lh-
incubation with different concentrations of
adriamycin is shown in Figure 3. In the wild-type
tumour adriamycin doses from 5 x 10-4-5 x 10-2
mgml-l resulted in G2+M accumulation, and the
maximum perturbation was found for the dose,
5 x 10-3 mgml-1. After Day 1 or 2 the harvest
resulted in low cell yields and much debris with
doses where G2 +M accumulations were found.
This phenomenon was probably caused by drug-
induced cell kill, and flow cytometry was therefore
not possible. The maximum dose applied
(101mgml-1) caused no detectable changes in the
DNA histograms. In contrast to this, a high drug
concentration (10-1 mgml-P) in the 2 resistant
tumours resulted in an increase of G2 +M cells,
decreasing to control values on Day 4. Adriamycin
concentrations < 10-2mgml- had no effect on
the G2 +M fraction.
Figure 4 shows a sequence of DNA histograms of
the wild-type tumour, illustrating the cell cycle
effect of continuous exposure to adriamycin for the
dose of 10-3mgml -1. The results of continuous
incubation on the G2 +M fraction, for different
doses, are shown in Figure 5. Continuous drug
exposure with adriamycin concentration
> 10-3mgml-I resulted in a cell kill which made
flow cytometric DNA analysis impossible after 12h
for all 3 tumours. In the wild-type tumour
concentrations from 5 x 10-5-1 x 10-3mgml-1
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Figure 3 Comparison of cells in G2 +M after treatment with different doses of adriamycin (mgml-1) for
1 h. (a) the "wild-type" tumour sensitive to adriamycin, (b) the near-tetraploid tumour resistant to
adriamycin, (c) the hyperdiploid tumour resistant to adriamycin.500 S.A. ENGELHOLM et al.
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Figure 4 DNA histograms of the wild-type tumour continuously incubated with adriamycin (10-3 mgml-').
(a) before incubation, G,: 44.5%, S: 46.5%, G2+M: 9.0%; (b) 12h after plating, Gl: 25.7%, S: 57.9%,
G2+M: 16.4%: (c) 24h after plating, G1: 5.2%, S: 52.7%, G2+M: 42.1%.
90 -
80 -o 10-'
70 -
60 - \ \5 x 10-S
50
40-
0
30
10~~~~~~~~
0 1 2 3 4
90 -
80 -
70 -
5 x 10-4
10-4
5 x 10-6
10-5
C
60 -
50 -
40 -
b
90 -
80 -
70 -
60 -
50
40 -
30 -/10-4
20 ',0
10 1 C
0 1 2 3 4
c
10 10-4
10-6
23
0 1 2 3 4
Time (days)
Figure 5 Comparison of cells in G2 +M after continuous exposure to different doses of adriamycin
(mgml-1). (a) the "wild-type" tumour sensitive to adriamycin, (b) the near-tetraploid tumour resistant to
adriamycin, (c) the hyperdiploid tumour resistant to adriamycin.
resulted in an accumulation in the G2 + M phase.
In contrast to the 1 h experiment, the harvest
resulted in sufficient cell yields for flow cytometric
DNA analysis until Day 3 with no indication of cell
death. In the 2 resistant tumours continuous
incubation resulted in no detectable effect on the
G2 + M phase (Figures 5b and 5c).
Discussion
This study has demonstrated that flow cytometric
DNA analysis can be used to evaluate the
sensitivity of three Ehrlich ascites tumours after in
vitro exposure to adriamycin. In in vitro sensitivity
testing it is essential to correlate the results with the
in vivo sensitivity of the tumours. The data herein
presented indicate that drug-induced cell cycle
perturbation in vitro correlates well with the in vivo
sensitivity of the three Ehrlich ascites tumours. It
has been shown that anthracyclines cause a dose-
dependent cell kill of the sensitive tumour,
demonstrated by increase in life-span and decrease
in tumour cell volume, whereas no effect was found
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upon the two resistant tumours (Dan0, 1971;
1972a; 1972b).
Flow cytometric DNA analysis was suitable for
monitoring the adriamycin-induced accumulation of
cells in the G2+M phase of the sensitive wild-type
tumour in the I h incubation experiment as well as
in the continuous incubation experiment. However,
the results were different in some aspects.
Monitoring of the cell cycle changes of the wild-
type tumour during continuous incubation was only
possible at adriamycin concentrations of
< 10-3mgml-1, whereas sufficient cell yield was
obtained in the 1 h incubation procedure for doses
<.0- I mgml 1. Continuous adriamycin incubation
caused an accumulation of cells in G2 +M
for concentrations 10-fold lower than after 1 h
exposure. The increase of the G2+M fraction in the
continuous incubation experiment was maximal on
days 2-4, whereas concentrations of 10-3mgmIP'
and 5xlO3mgml-I resulted in an almost
complete accumulation of cells in G2+M on Day 1
in the 1 h experiment. The differences in the results
in the two incubation procedures correlate well with
results obtained for human lymphoid cell line
exposed to adriamycin (Barlogie et al., 1976). The
changes in the cell cycle compartments are the net
results of the pretreatment fluxs, treatment-induced
changes in some of these fluxs and cell loss. The
explanation of the differences in the results of the
two incubation procedures might be that 1 h
adriamycin exposure (10-3mgMml1 and
5x10 -3mgml- ) does not affect the G1 and S
phases, but induces a block in G2+M, followed by
cell death. Continuous drug exposure resulted in a
decreased flux of cells from S to G2+M and delay
in G2 +M phase.
Drug-induced changes in the cell cycle are dose-
dependent. In the two resistant tumours the
maximum dose applied (10- mgml-1) also
resulted in an accumulation of cells in G2+M
phase (Figure 3b and 3c). The G2+M fraction was
falling to values almost identical to the controls on
Day 4, and the cell yield did not indicate cell death.
In the sensitive tumour the adriamycin dose of
10- 1 mgml-1 induced a "freezing" of the cell cycle,
resulting in no detectable effect (Figure 3a), a
phenomenon previously described with cultured
human lymphoblasts exposed to high doses of
adriamycin (Krishan & Frei, 1976) and VP-16-213
(Drewinko & Barlogie, 1976).
The continuous incubation procedure is
considered the more feasible of the two methods for
use as a clinical drug sensitivity test. Continuous
exposure involves fewer steps than the 1 h method,
the loss of cells caused by washing out adriamycin
after I h is thus avoided, and the time interval
where a G2+M accumulation is detectable is
longer when the tumour cells are incubated
continuously.
In both procedures it is important to test an
adequate number of dose levels to ensure doses
within the range of concentrations causing a
detectable drug effect. The use of too few dose levels
involves the risk of testing only low doses, with no
effect, or high doses, resulting in the observed
"freezing" phenomenon.
A simple estimate of the sensitivity of a tumour
to adriamycin could be that concentration of the
drug which results in maximum accumulation of the
cells in G2+M. For the wild-type tumour the
estimate would be 1O-3mgml-1 and 10l 1mgml -
for the resistant tumours after 1 h incubation.
A number of chemotherapeutic agents have a
cycle-specific effect, and therefore it may be
possible to use the method to evaluate sensitivity to
agents other than adriamycin. In a recent study,
flow cytometric DNA analysis performed on
sequential fine-needle aspirates from human
tumours during chemotherapy demonstrated
pronounced drug-induced cell cycle perturbations
(Vindelqv et al., 1982). We therefore consider it
possible to modify and extend the methods as a
sensitivity test for human malignant tumours.
However, therapy-induced cell cycle perturbations
which are not accompanied by cell kill (Terasima &
Tolmach, 1963) may prove to be a limitation in
using flow cytometry for in vitro sensitivity testing.
The methods described in this study would
overcome some of the limitations of the in vitro
clonogenic assay (Hamburger & Salmon, 1977).
The methods demand only that the tumour cells are
maintained through a single cell cycle; the
determination of colony-forming cells is
unnecessary. The flow cytometric technique permits
the determination of the DNA-index (Barlogie et
al., 1978), which ensures that, as far as DNA
content is concerned, the cells tested in vitro are
representative of the main cell population of the
tumour. Finally, the sensitivity test presented
provides conclusive results within a few days.
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